Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients.

Carcinogenesis - 1 Aug 2010

Chen Meng, Gu Jian, Delclos George L, Killary Ann M, Fan Zhen, Hildebrandt Michelle A T, Chamberlain Robert M, Grossman H Barton, Dinney Colin P, Wu Xifeng

Abstract excerpt

The phosphoinositide-3 kinase (PI3K)-AKT- mammalian target of rapamycin (mTOR) pathway is an important cellular pathway controlling cell growth, tumorigenesis, cell invasion and drug response. We hypothesized that genetic variations in the PI3K-AKT-mTOR pathway may affect the survival in muscle i...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neoplasm Invasiveness
Share to Neoplasm Metastasis
Share to Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins c-akt

Share to Regression Analysis

Share to Survival Analysis

Share to TOR Serine-Threonine Kinases

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 20530239
DOI: 10.1093/carcin/bgq110
PMCID: PMC2915631

Genes

AKT2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20530239-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients.PMID 20530239Read ↗

Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk.Semantic proximity Read ↗

Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted TherapeuticsSemantic proximity Read ↗

Genomic Alterations of Signaling and DNA Damage Repair Pathways in Non-Muscle Invasive Bladder Cancer.Semantic proximity Read ↗

Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.Semantic proximity Read ↗

Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical ChallengesSemantic proximity Read ↗

Associations of genetic polymorphisms in pTEN/AKT/mTOR signaling pathway genes with cancer risk: A meta-analysis in Asian population.Semantic proximity Read ↗

Genetic variants in the mTOR pathway with renal cancer risk and subtypes in East Indian population.Semantic proximity Read ↗

Polymorphisms in the mTOR gene and risk of sporadic prostate cancer in an Eastern Chinese population.Semantic proximity Read ↗

Genetic polymorphisms of mTOR and cancer risk: a systematic review and updated meta-analysis.Semantic proximity Read ↗

Significant benefit of everolimus in a patient with urothelial bladder cancer harboring a rare M1043I mutation of PIK3CA.Semantic proximity Read ↗

Association of mTOR polymorphisms with cancer risk and clinical outcomes: a meta-analysis.Semantic proximity Read ↗

Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.